Monday Jan 16, 2023

The NICHE-2 Study Discussion with Dr. Myriam Chalabi

The NICHE-2 study offered neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer patients, resulting in a major pathologic response in 95% of patients and 67% pCR. In discussion with the lead author, Dr. Myriam Chalabi - Medical Oncologist at the Netherlands Cancer Institute.  
 
Contact us at info@oncbrothers.com
 

Comment (0)

No comments yet. Be the first to say something!

Oncology Brothers

Podcast Powered By Podbean

Version: 20241125